环丙沙星：概述与前瞻性评估。 - Suppr

Suppr

超能文献

Ciprofloxacin: an overview and prospective appraisal.

作者信息

Neu H C

出版信息

Am J Med. 1987 Apr 27;82(4A):395-404.

PMID:3578329

Abstract

摘要

相似文献

Ciprofloxacin: an overview and prospective appraisal.

Am J Med. 1987 Apr 27;82(4A):395-404.

Treatment of common infectious disorders.

W V Med J. 1976 Jun;72(6):135-45.

Ciprofloxacin: an update on clinical experience.

Am J Med. 1987 Apr 27;82(4A):381-6.

[Rational and economic antibiotics therapy in medical practice and outpatient clinics].

Dtsch Med Wochenschr. 1984 May 25;109(21):834-40. doi: 10.1055/s-2008-1069284.

Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society.

CMAJ. 1994 Mar 1;150(5):669-76.

Prescribing considerations in fluoroquinolone therapy.

Pharmacotherapy. 1993 Mar-Apr;13(2 Pt 2):39S-44S.

Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections.

Rev Infect Dis. 1988 May-Jun;10(3):528-43. doi: 10.1093/clinids/10.3.528.

[Oral ciprofloxacin therapy in juvenile patients with cystic fibrosis--results of a prospective pilot study].

Kinderarztl Prax. 1993 Aug;61(6):211-4.

The role of the fluoroquinolones in primary care practice.

Clin Invest Med. 1989 Feb;12(1):71-3.

Cephalexin: a review of its antibacterial, pharmacological and therapeutic properties.

Drugs. 1972;3(1):9-78. doi: 10.2165/00003495-197203010-00002.

引用本文的文献

Mechanistic insight of cell anti-proliferative activity of fluoroquinolone drug-based Cu(II) complexes.

Mol Divers. 2022 Apr;26(2):869-878. doi: 10.1007/s11030-021-10199-2. Epub 2021 Mar 1.

Risk factors associated with fluoroquinolone-resistant enterococcal urinary tract infections in a tertiary care university hospital in north India.

Indian J Med Res. 2016 Oct;144(4):604-610. doi: 10.4103/0971-5916.200897.

1-Cyclo-propyl-6-fluoro-7-(4-nitro-so-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid.

Acta Crystallogr Sect E Struct Rep Online. 2009 Jul 31;65(Pt 8):o2053. doi: 10.1107/S1600536809029729.

Modeling antibiotic resistance to project future rates: quinolone resistance in Escherichia coli.

Eur J Clin Microbiol Infect Dis. 2010 Mar;29(3):353-6. doi: 10.1007/s10096-009-0862-x. Epub 2010 Jan 30.

Growth in the presence of salicylate increases fluoroquinolone resistance in Staphylococcus aureus.

Antimicrob Agents Chemother. 1999 Apr;43(4):990-2. doi: 10.1128/AAC.43.4.990.

In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.

Antimicrob Agents Chemother. 1995 Oct;39(10):2210-6. doi: 10.1128/AAC.39.10.2210.

Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society.

CMAJ. 1994 Mar 1;150(5):669-76.

Bacterial resistance to fluoroquinolones: lessons to be learned.

Infection. 1994;22 Suppl 2:S140-7. doi: 10.1007/BF01793579.

Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Drugs. 1988 Apr;35(4):373-447. doi: 10.2165/00003495-198835040-00003.

Fluoroquinolone antimicrobial agents.

Clin Microbiol Rev. 1989 Oct;2(4):378-424. doi: 10.1128/CMR.2.4.378.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验